Highlights

Public-Private Partnership Between NIAID and Sequella Yields New TB Drug for Clinical Testing Statement from the NIH
Read More

Highlights

March 24, 2008 - NIAID Statement on World Tuberculosis Day
Read More


Welcome to Sequella

Sequella is a clinical stage biopharmaceutical company focused on commercializing improved treatment paradigms for diseases of epidemic potential. The company leverages its global influence, R&D platforms and infectious disease expertise to proactively address emerging health threats.

Through focused execution, clear commercialization pathways, and strategic partnerships, Sequella intends to commercialize a broad product portfolio designed to treat global health threats with significant market opportunity.

© 2006 Sequella, Inc.